by Gregg A. Masters, MPH
In a sea of relentless ‘acronym soup’ that peppers the landscape and too often separates us from the constituency we ostensibly serve (patients) via added layers of dubious complexity to the dysfunctional 
U.S. healthcare delivery and financing ecosystem, the Centers for Medicare and Medicaid Innovation (CMMI) has added the ‘Community Health Access and Rural Transformation (CHART) Model‘ to our expanding nomenclature.
While we work through and perhaps finally remedy chronic and historically prevailing health in-equities across both urban and sub-urban settings vs. that typically found in rural markets driven by a ‘book of business’ (or financial class) series of incentives, the CHART model:
…aims to continue addressing disparities by providing a way for rural communities to transform their health care delivery systems by leveraging innovative financial arrangements as well as operational and regulatory flexibilities.
No doubt a noble cause and the ‘innovators’ at CMMI are to be recognized and commended for their efforts to make a meaningful difference in the lives of American’s who do not benefit from the typical healthcare asset concentrations in major markets – primarily urban and sub-urban.
While the range of ACO models – both commercial and public sector, i.e., Medicare and Medicaid – are seen by many as tepid responses to an uncharacteristically change or reform resistant healthcare economy fueled principally by still prevailing fee-for-service production incentives, we’re still early on in the evolution of this managed competition model of healthcare innovation, i.e., the ‘efficacy’ jury of ACOs to deliver on the ‘triple aim’ in aggregate is still out.
So read on and see what you think about the prospects of the CHART model to materially impact healthcare delivery while adding value to restraining the cost basis for accessing essential health services for largely under-served communities.
As always, your thoughts and comments are welcome.
==##==
acowatch.me 
https://www.jaisurgicals.com/
Jai Surgicals Limited introduced its patented disposable safety scalpel into the USA market in 2002 and thereby established its pioneer status. Since then, the Organization’s commitment to its policy of contributing to the reduction of sharps injury, has led to the development of several safety scalpel solutions. Each safety scalpel solution has been developed with a focus on user preferences and Institutional budgets. Jai Surgicals Limited believes user acceptance and satisfaction is key to the reduction of sharps injury while keeping implementation costs low.
These product innovations have been built on almost 50 years of experience manufacturing surgical blades & scalpels, dermal curette, biopsy punch, etc. The company’s Surgeon brand products are recognized in over 70 countries where they are distributed by our partners with some relationships spanning over two decades. Jai Surgicals Ltd. is also the leading private label manufacturer for Industry leaders worldwide. We value our relationships and promise timely deliveries, service, quality, value for money, co-operation, respect, courtesy and loyalty.